SCHEMBL5387330

SCHEMBL5387330

CC[CH]Oc1cccc(CCCCCCCCCCCCCCC)c1

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.56
PPARG P37231 5/20 0.56
LPL P06858 2/20 0.49
LIPG Q9Y5X9 2/20 0.49
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8957630 1.00 PPARA (0.56) PPARAPPARGLPLLIPGCNR1
SCHEMBL11158420 0.89 PPARA (0.55) PPARAPPARGLPLLIPGCNR1
SCHEMBL5253611 0.86 PPARA (0.57) PPARAPPARGLPLLIPGCNR1
SCHEMBL9011837 0.86 PPARA (0.57) PPARAPPARGLPLLIPGCNR1
SCHEMBL7603007 0.84 PPARA (0.59) PPARAPPARGLPLLIPGCNR1
SCHEMBL29693068 0.82 PPARA (0.63) PPARAPPARGLPLLIPG
SCHEMBL176242 0.82 PPARA (0.63) PPARAPPARGLPLLIPG
SCHEMBL28547948 0.82 PPARA (0.63) PPARAPPARGLPLLIPG
SCHEMBL27830388 0.82 PPARA (0.63) PPARAPPARGLPLLIPG
SCHEMBL9819438 0.82 PPARA (0.63) PPARAPPARGLPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312337-B2 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY (US) 2007-12-25 US claimed
US-7268235-B2 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY (US) 2007-09-11 US claimed
US-20060074245-A1 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY 2006-04-06 US claimed
US-20060069262-A1 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY 2006-03-30 US claimed
US-6657083-B2 Photographic couplers; acylation amine group in position 2 EASTMAN KODAK COMPANY 2003-12-02 US claimed
US-6613943-B2 Intermediates for 4-substituted-2,5-diaminophenol derivatives as phenolic cyan couplers for color photography; deblocking the 2-acyl group by hydrolysis EASTMAN KODAK COMPANY 2003-09-02 US claimed
US-20030109716-A1 5-ACYLAMINO-2-AMINO-4-SUBSTITUTED-PHENOL COMPOUNDS AND METHOD OF USING THEM EASTMAN KODAK COMPANY 2003-06-12 US claimed
US-20030109753-A1 4-acylamino-2-hydroxy-5-substituted-acylanilide compounds and method of using them EASTMAN KODAK COMPANY 2003-06-12 US claimed
US-6525219-B1 Chemical intermediates for cyan dye forming couplers; deblocking, hydrolysis, acylation EASTMAN KODAK COMPANY 2003-02-25 US claimed
US-6476202-B1 5-acylamino-2-arylazo, nitro, or nitroso-4-substituted-phenol compounds and method of using them EASTMAN KODAK COMPANY 2002-11-05 US claimed
US-7312337-B2 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY (US) 2007-12-25 US disclosed
US-7268235-B2 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY (US) 2007-09-11 US disclosed
US-20060074245-A1 Method for preparation of N-pyrazolylamidoximes EASTMAN KODAK COMPANY 2006-04-06 US disclosed
US-20060069262-A1 Oxadiazoles and their manufacture EASTMAN KODAK COMPANY 2006-03-30 US disclosed
US-6657083-B2 Photographic couplers; acylation amine group in position 2 EASTMAN KODAK COMPANY 2003-12-02 US disclosed
US-4717651-A SULFONAMIDOPHENOL DERIVATIVES AS COLOR STAIN INHIBITORS FUJI PHOTO FILM CO., LTD. (JP) 1988-01-05 US disclosed
US-4584264-A POLYHYDROXYAROMATIC SULFONAMIDE AS STAIN INHIBITOR FUJI PHOTO FILM CO., LTD. (JP) 1986-04-22 US disclosed
EP-0113484-A1 Novel 2-equivalant cyan-forming couplers and photographic elements containing them AGFA-GEVAERT N.V. (BE) 1984-07-18 EP disclosed
US-4171975-A MAGENTA COUPLER AND AN AMIDE KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1979-10-23 US disclosed
US-4073651-A Image-forming layer containing silver halide emulsion and magenta coupler MITSUBISHI PAPER MILLS, LTD. (JA) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109753-A1 4-acylamino-2-hydroxy-5-substituted-acylanilide compounds and method of using them CBR3, AADAC, HAAO PPARA 1501/4885PPARG 2639/4885LPL 1558/4885
US-20030109716-A1 5-ACYLAMINO-2-AMINO-4-SUBSTITUTED-PHENOL COMPOUNDS AND METHOD OF USING THEM AADAT, AAAS, ANXA7 PPARA 329/4885PPARG 438/4885LPL 2751/4885
US-20060069262-A1 Oxadiazoles and their manufacture OXA1L, CYP1B1, OXER1 PPARA 3440/4885PPARG 3218/4885LPL 4768/4885
US-20060074245-A1 Method for preparation of N-pyrazolylamidoximes KCNH1, KCNJ2, KCNH2 PPARA 3200/4885PPARG 2323/4885LPL 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.